apple-stock-split-causes-dow-jones-industrial-average-shuffle;-salesforce,-amgen,-honeywell-to-make-entry

Apple Stock Split Causes Dow Jones Industrial Average Shuffle; Salesforce, Amgen, Honeywell To Make Entry

SPGI), on Monday announced certain changes to the Dow Jones Industrial Average (DJIA) composition, effective Aug. 31.” data-reactid=”19″ type=”text”>The S&P Dow Jones Indices, a division of S&P Global (NYSE: SPGI), on Monday announced certain changes to the Dow Jones Industrial Average (DJIA) composition, effective Aug. 31.

Salesforce.com Inc. (NYSE: CRM) will replace Exxon Mobil Corp. (NYSE: XOM), biotech company Amgen Inc. (NASDAQ: AMGN) will replace Pfizer Inc. (NYSE: PFE), and Honeywell International Inc. (NYSE: HON) will replace Raytheon Technologies Corp. (NYSE: RTX).” data-reactid=”21″ type=”text”>Cloud computing solutions provider Salesforce.com Inc. (NYSE: CRM) will replace Exxon Mobil Corp. (NYSE: XOM), biotech company Amgen Inc. (NASDAQ: AMGN) will replace Pfizer Inc. (NYSE: PFE), and Honeywell International Inc. (NYSE: HON) will replace Raytheon Technologies Corp. (NYSE: RTX).

AAPL) declared a 1:4 stock split, which would also come into effect on Aug. 31.” data-reactid=”22″ type=”text”>The decision to replace three stocks in the index came after Apple Inc (NASDAQ: AAPL) declared a 1:4 stock split, which would also come into effect on Aug. 31.

What’s Next: To ensure consistency, new divisors will be used to rebalance the index, specifics of which will be available in the S&P Dow Jones Indices FTP (EDX) site on Aug. 28, according to the statement.” data-reactid=”28″ type=”text”>What’s Next: To ensure consistency, new divisors will be used to rebalance the index, specifics of which will be available in the S&P Dow Jones Indices FTP (EDX) site on Aug. 28, according to the statement.

Among the three new entrants, Salesforce.com shares traded 3% higher at $214.8 in the after-hours session Monday. Amgen shares traded 4% higher at $245, and Honeywell shares were up 3.8% at $165.5.

  • Tesla Reportedly Shrinks Model 3 ‘Frunk,’ Leading To Speculations Over Heat Pump
  • Novartis Skin Cancer Drug Combination Involving Spartalizumab Fails Clinical Trial
  • Palantir Remains Unprofitable Ahead Of Planned Direct Listing: Report
  • Post navigation

    Leave a Comment

    Your email address will not be published. Required fields are marked *

    Scroll to Top